Humira

E697096

Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (1)

Label Occurrences
Humira canonical 1

Statements (48)

Predicate Object
instanceOf biologic medication
monoclonal antibody
tumor necrosis factor inhibitor
approvalBy European Medicines Agency NERFINISHED
U.S. Food and Drug Administration NERFINISHED
approvalYear 2002
bindsTo membrane-bound TNF-alpha
soluble TNF-alpha
blackBoxWarning malignancy
serious infections
commonAdverseEffect headache
injection site reaction
upper respiratory tract infection
contraindication active serious infection
moderate to severe heart failure
developer AbbVie NERFINISHED
hasATCCode L04AB04
hasDosageForm pre-filled pen
pre-filled syringe
hasDrugClass TNF-alpha inhibitor
immunosuppressive agent
hasGenericName adalimumab
hasINN adalimumab
hasRouteOfAdministration subcutaneous injection
indication Crohn's disease
ankylosing spondylitis
hidradenitis suppurativa
juvenile idiopathic arthritis
non-infectious intermediate uveitis
non-infectious panuveitis
non-infectious posterior uveitis
plaque psoriasis
psoriatic arthritis
rheumatoid arthritis
ulcerative colitis
uveitis
isAdministeredBy patient self-injection
isBiologic true
isBiosimilarAvailable true
mechanismOfAction binds to TNF-alpha and blocks its interaction with TNF receptors
molecularType recombinant human IgG1 monoclonal antibody
originalDeveloper Abbott Laboratories NERFINISHED
pregnancyCategoryUS B
reduces inflammatory response mediated by TNF-alpha
requiresMonitoring hepatitis B reactivation
signs of infection
tuberculosis
targets tumor necrosis factor alpha NERFINISHED

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

AbbVie notableProduct Humira